Financial Data and Key Metrics Changes - Sales for Q2 2024 were $5.7 billion, with core revenue declining by 3.5% year-over-year [10] - Gross profit margin for Q2 was 59.7%, and adjusted operating profit margin increased by 60 basis points to 27.3% [10] - Adjusted diluted net earnings per share were $1.72, remaining flat year-over-year [11] - Free cash flow generated in the quarter was $1.1 billion, with a year-to-date free cash flow to net income conversion ratio of 129% [11] Business Line Data and Key Metrics Changes - In the biotechnology segment, core revenue declined by 7%, with bioprocessing down high single digits and discovery and medical business down mid-single digits [12] - Life Sciences segment saw a core revenue decrease of 5.5%, with capital equipment investments remaining constrained [17] - Diagnostics segment experienced a core revenue increase of 3%, driven by mid-single digit growth in Clinical Diagnostics [20] Market Data and Key Metrics Changes - Core revenues in developed markets were down low single digits, while high growth markets declined high single digits, including a high-teens decline in China [10] - Bioprocessing demand in the U.S. and Europe improved, with orders increasing high single digits sequentially [8] - In China, bioprocessing demand remained weak as customers managed liquidity, with expectations for improvement in 2025 [8][55] Company Strategy and Development Direction - Danaher aims for sustainable long-term value creation, expecting high single-digit core revenue growth with a differentiated margin and cash flow profile [9] - The company continues to invest in innovation to support customers in developing life-changing therapeutics [15] - Share repurchases reflect confidence in long-term organic growth, earnings, and cash flow outlook, while maintaining a bias towards M&A for capital deployment [11][44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in bioprocessing and the overall market conditions, with expectations for a low single-digit core revenue decline in Q3 2024 [24] - The company anticipates continued improvement in bioprocessing orders and a return to normal order patterns as destocking is largely complete [72] - Management highlighted the importance of the funding environment for smaller biotech customers and the expected impact on order volumes [73] Other Important Information - Danaher released its 2024 Sustainability Report, committing to science-based greenhouse gas emission reduction targets [23] - The company received FDA approvals for new diagnostic tests, enhancing its product offerings and market position [22] Q&A Session Summary Question: Insights on bioprocessing consumables and capital equipment - Management noted that ordering patterns for consumables have returned to normal, while capital equipment remains slightly constrained for smaller customers [29] Question: Q3 guidance and seasonal impacts - Management expects low single-digit revenue decline in bioprocessing for Q3, with normal seasonal patterns anticipated [35][36] Question: Competitive pricing environment - Pricing was up 100 basis points in Q2, with expectations to remain above historical averages for 2024 [51] Question: China market dynamics - Management indicated that increased coding activity in China is not expected to convert to orders until 2025 due to pending stimulus funding [55][76] Question: Life Sciences segment performance - The Life Sciences segment remains under pressure, with capital equipment demand weak and expectations for stabilization in the second half of 2024 [58][59]

Company Performance - Danaher reported quarterly earnings of $1.72 per share, exceeding the Zacks Consensus Estimate of $1.57 per share, but down from $2.05 per share a year ago, indicating an earnings surprise of 9.55% [1] - The company posted revenues of $5.74 billion for the quarter, surpassing the Zacks Consensus Estimate by 2.78%, compared to $7.16 billion in the same quarter last year [1] - Over the last four quarters, Danaher has consistently surpassed consensus EPS and revenue estimates [1] Stock Performance - Danaher shares have increased approximately 8.5% since the beginning of the year, while the S&P 500 has gained 16.7% [2] - The current estimate revisions trend for Danaher is unfavorable, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [4] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.70 on revenues of $5.79 billion, and for the current fiscal year, it is $7.62 on revenues of $23.88 billion [4] - The sustainability of Danaher's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [2][3] Industry Context - The Diversified Operations industry, to which Danaher belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable industry outlook [5] - IAC, another company in the same industry, is expected to report a quarterly loss of $0.39 per share, reflecting a year-over-year change of +48.7%, with revenues projected at $948.89 million, down 14.6% from the previous year [5]

Second Quarter 2024 Performance - Revenue decreased by 30% to $5743 million compared to $5912 million in Q2 2023[4, 5] - Core revenue declined by 35%[4] - Acquisitions contributed +20% to revenue[4] - Foreign exchange rates had a -15% impact on revenue[4] - Adjusted diluted net earnings per common share from continuing operations decreased by 06%[4] - Free cash flow performance decreased by 145%[6] - Adjusted operating profit margin increased by +60 BPS from 267% to 273%[6, 7] Segment Performance - Biotechnology revenue decreased by 90%, with core revenue down 70% and a 20% negative impact from FX[8] - Biotechnology adjusted operating profit margin increased by +20 BPS from 393% to 395%[8, 9] - Life Sciences revenue decreased by 15%, with core revenue down 55%, acquisitions contributing +60%, and a -20% impact from FX[10] - Life Sciences adjusted operating profit margin decreased by -360 BPS from 247% to 211%[10, 11] Forecasted Core Sales Decline and Adjusted Operating Profit Margin - The company forecasts a low-single digit percentage core sales decline for the three-month period ending September 27, 2024, compared to the comparable 2023 period[27] - The company forecasts a low-single digit percentage core sales decline for the year ending December 31, 2024, compared to the comparable 2023 period[27] - Adjusted operating profit margin is forecasted to be approximately 260% for the three-month period ending September 27, 2024[27] - Adjusted operating profit margin is forecasted to be approximately 290% for the year ending December 31, 2024[27]

Key Points - Danaher Corporation reported net earnings of $907 million for the quarter ended June 28, 2024, translating to $1.22 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.72 [1][5][11] - Revenues decreased by 3.0% year-over-year to $5.7 billion, with non-GAAP core revenue down 3.5% [1][11] - Operating cash flow was reported at $1.4 billion, while non-GAAP free cash flow was $1.1 billion [1][12] - The company expressed satisfaction with the performance of its bioprocessing business and Cepheid, indicating market share gains in molecular testing [1][3] - Danaher anticipates low-single digit declines in non-GAAP core revenue for both the third quarter and full year 2024 [1][11] Financial Performance - For the three-month period ended June 28, 2024, total sales were $5.743 billion, down from $5.912 billion in the same period last year [5][11] - Gross profit for the quarter was $3.428 billion, with operating profit at $1.168 billion [6][11] - The company reported a year-over-year decline in net earnings from continuing operations, which was $907 million compared to $920 million in the previous year [5][11] Segment Performance - The biotechnology segment experienced a sales decline of 9.0%, while life sciences and diagnostics segments saw declines of 1.5% and growth of 1.5%, respectively [11] - Core sales growth was reported as a decline of 3.5% for the three-month period, with a forecasted decline of low-single digits for the upcoming periods [11][12] Cash Flow Analysis - Total cash flow from continuing operations was $1.417 billion for the quarter, down from $1.646 billion year-over-year [12] - Free cash flow from continuing operations was reported at $1.131 billion, reflecting a decrease from $1.319 billion in the previous year [12]

Exhibit 99.1 Innovation at the speed of life Danaher Reports Second Quarter 2024 Results WASHINGTON D.C., July 23, 2024 -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results • Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.72. • Revenues decreased ...

Core Viewpoint - Danaher Corporation is expected to face a challenging quarter due to inventory destocking in the bioprocessing market, but the stock has already corrected significantly, indicating that most negatives are priced in. A medium to long-term recovery is anticipated starting in FY25, maintaining a buy rating on the stock [4]. Company Performance - The stock experienced a high single-digit percentage increase from April to mid-June but has since returned to previous levels [4]. - Earnings report is scheduled for July 23, with expectations of a downbeat quarter due to industry commentary and regulatory delays [4]. Market Conditions - The bioprocessing market has seen inventory destocking as companies reduce excess inventory built during COVID-19 supply chain constraints [4]. - Peers in the bioprocessing sector, such as Avantor and Sartorius AG, have provided negative commentary, indicating no signs of market recovery yet [4]. - Citigroup downgraded Avantor, citing concerns over elevated customer inventory levels [4]. Future Outlook - Expectations for DHR's earnings are low, suggesting limited downside risk [4]. - The second half of the year may shift investor focus towards 2025, with potential positive commentary expected from management regarding future outlook [4]. - The Chinese government's plans for equipment upgrades could benefit DHR's sales in 2H 2024 and beyond [4]. - A potential reversal in the interest rate cycle may encourage customer investments in equipment, supporting DHR's demand [4]. Legislative Impact - The BioSecure Act, if passed, could provide a competitive advantage to U.S. Medtech/Healthcare Equipment firms, benefiting DHR [4]. Financial Estimates - Consensus EPS estimates show growth accelerating from FY25, with projected EPS of 8.67 in Dec 2025, reflecting a 14.03% YoY growth [5]. - Revenue estimates indicate a decline in Dec 2024 to 23.84 billion, followed by growth to 25.82 billion in Dec 2025, representing an 8.29% YoY increase [6]. - The stock has traded at a historical forward P/E of 29.75x, and while current P/E is slightly higher, it is trading at a discount based on FY25 and FY26 EPS estimates [6].

Danaher Corporation (DHR) is scheduled to release second-quarter 2024 results on Jul 23, before market open.The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.6%. In the last reported quarter, its earnings of $1.92 per share beat the consensus estimate of $1.72 by 11.6%.Let’s see how things have shaped up for Danaher this earnings season.Key Factors and Estimates for Q2Strength in the molecular diagnostics business, driven by inc ...

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced the lau ...

Core Viewpoint - Danaher (DHR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks rating upgrade reflects an improvement in Danaher's earnings outlook, which is expected to positively impact its stock price [2]. - For the fiscal year ending December 2024, Danaher is projected to earn $7.63 per share, representing a year-over-year increase of 0.7% [5]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for Danaher has increased by 0.1%, indicating a trend of rising earnings estimates [5]. - The correlation between earnings estimate revisions and near-term stock movements is strong, with institutional investors often adjusting their valuations based on these estimates [3][4]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, indicating superior earnings estimate revisions [6][7]. - Stocks rated Zacks Rank 1 (Strong Buy) have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the Zacks Rank system [4].

Company Performance - Danaher (DHR) has returned 6.4% year-to-date, outperforming the average loss of 3.1% in the Conglomerates group [2][3] - The Zacks Consensus Estimate for DHR's full-year earnings has increased by 0.1% in the past quarter, indicating improved analyst sentiment [2] - Honeywell International Inc. (HON) has also outperformed the sector with a year-to-date return of 2.9% and a consensus EPS estimate increase of 2.5% over the past three months [2][3] Industry Overview - Danaher is part of the Diversified Operations industry, which includes 24 companies and currently ranks 34 in the Zacks Industry Rank [3] - Stocks in the Diversified Operations industry have collectively lost about 3.1% year-to-date, highlighting Danaher's relative strength within this group [3] - The Conglomerates sector, which includes 24 individual stocks, ranks 1 in the Zacks Sector Rank, indicating strong overall performance [1]